Advances in metanephrine testing for the diagnosis of pheochromocytoma

Clinics in Laboratory Medicine

Volumn 24, Issue 1, 2004, Pages 85-103

  Singh, Ravinder J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CATECHOLAMINE; CHLORPROMAZINE; DIATRIZOATE; DOPAMINE; EPHEDRINE; HYDRAZINE; IMIPRAMINE; METADRENALIN; METHYLDOPA; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PHENACETIN; VANILMANDELIC ACID;

CHEMICAL ANALYSIS; DIAGNOSTIC PROCEDURE; HUMAN; LABORATORY TEST; METHODOLOGY; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY;

ADRENAL GLAND NEOPLASMS; CHEMISTRY, CLINICAL; HUMANS; METANEPHRINE; PHEOCHROMOCYTOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 2442534005     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.01.015     Document Type: Review

References (42)

1. Bravo EL. Pheochromocytoma. Curr Ther Endocrinol Metab 1997;6:195-7.
2. Walther MM, Keiser HR, Linehan WM. Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol 1999;17:35-9.
3. Bravo EL. Pheochromocytoma. Cardiol Rev 2002;10:44-50.
4. Beatty OL, Russell CF, Kennedy L, Hadden DR, Kennedy TL, Atkinson AB. Phaeochromocytoma in Northern Ireland: a 21 year review. Eur J Surg 1996;162:695-702.
5. Schulz C, Eisenhofer G, Lehnert H. Principles of catecholamine biosynthesis, metabolism and release. Front Horm Res 2004;31:1-25.
6. Isobe K, Takekoshi K, Kawakami Y, Nakai T. Pathogenesis of pheochromocytoma. Front Horm Res 2004;31:26-44.
7. Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HPH. The genetic basis of pheochromocytoma. Front Horm Res 2004;31:45-60.
8. Kaltsas GA, Papadogias D, Grossman AB. The clinical presentation (symptoms and signs) of sporadic and familial chromaflin cell tumours (phaeochromocytomas and paragangliomas). Front Horm Res 2004;31:61-75.
9. Eisenhofer G, Lenders JWM, Pacak K. Biochemical diagnosis of pheochromocytoma. Front Horm Res 2004;31:76-106.
10. Pacak K, Eisenhofer G, Ilias I. Diagnostic imaging of pheochromocytoma. Front Horm Res 2004;31:107-20.
11. Eisenhofer G, Goldstein DS, Kopin IJ, Crout JR. Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol 2003;14(3):193-212.
12. Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 1981;56:354-60.
13. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975. Mayo Clin Proc 1977;52:549-55.
14. Eisenhofer G, Walther M, Keiser HR, Lenders JW, Friberg P, Pacak K. Plasma metanephrines: a novel and cost-effective test for pheochromocytoma. Braz J Med Biol Res 2000;33:1157-69.
15. Eisenhofer G, Huynh TT, Hiroi M, Pacak K. Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Disord 2001;2:297-311.
16. Eisenhofer G, Lenders JW, Pacak K. Choice of biochemical test for diagnosis of pheochromocytoma: validation of plasma metanephrines. Curr Hypertens Rep 2002;4:250-5.
17. Eisenhofer G. Editorial: biochemical diagnosis of pheochromocytoma - is it time to switch to plasma-free metanephrines? J Clin Endocrinol Metab 2003;88:550-2.
18. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:315-29.
19. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Goldstein DS. Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography. Ann N Y Acad Sci 2002;970:170-6.
20. Roden M. How to detect pheochromocytomas? The diagnostic relevance of plasma free metanephrines. Wien Klin Wochenschr 2002;114:246-51.
21. Sawka AM, Singh RJ, Young WF. False positive biochemical testing for pheochromocytoma caused by surreptitious catecholamine addition to urine. Endocrinologist 2001;11:421-3.
22. Kudva YC, Sawka AM, Young WF. Clinical review 164 - the laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003;88:4533-9.
23. Baghai M, Thompson GB, Young WF Jr, Grant CS, Michels VV, van Heerden JA. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Archives of Surgery 2002;137:682-8 [discussion: 688-9].
24. Orchard T, Grant CS, van Heerden JA, Weaver A. Pheochromocytoma - continuing evolution of surgical therapy. Surgery 1993;114:1153-8 [discussion: 1158-9].
25. Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract 2000;6:249-52.
26. Young WF Jr. Pheochromocytoma and primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am 1997;26:801-27.
27. Young WF Jr. Pheochromocytoma and primary aldosteronism. Cancer Treat Res 1997;89:239-61.
28. Young WF Jr. Pheochromocytoma: issues in diagnosis & treatment. Compr Ther 1997;23:319-26.
29. Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000;29:159-85.
30. Lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, Kopin IJ. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 1993;39:97-103.
31. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998;83(6):2175-85.
32. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287:1427-34.
33. Sawka AM, Jaeschke R, Singh RJ, Young WF. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003;88:553-8.
34. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995;123:101-9.
35. Crout J, Sjoerdsma A. Turnover and metabolism of catecholamines in patients with pheochromocytoma. J Clin Invest 1964;43:94-102.
36. Akpunonu BE, Mulrow PJ, Hoffman EA. Secondary hypertension: evaluation and treatment. Dis Mon 1996;42:609-722 [erratum: Dis Mon 1997;43:62].
37. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001;12:173-8.
38. Grouzmann E, Fathi M, Gillet M, de Torrente A, Cavadas C, Brunner H, et al. Disappearance rate of catecholamines, total metanephrines, and neuropeptide Y from the plasma of patients after resection of pheochromocytoma. Clin Chem 2001;47:1075-82.
39. Taylor RL, Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clin Chem 2002;48:533-9.
40. Peaston RT, Lennard TW, Lai LC. Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma. J Clin Endocrinol Metab 1996;81:1378-84.
41. Ito Y, Obara T, Okamoto T, Kanbe M, Tanaka R, Iihara M, et al. Efficacy of single-voided urine metanephrine and normetanephrine assay for diagnosing pheochromocytoma. World J Surg 1998;22:684-8.
42. Lagerstedt SA, O'Kane DJ, Singh RJ. Analysis of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for diagnosis of pheochromocytoma. Clin Chem 2004;50:603-11.